3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
39
Colonic Neoplasms
10
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Unresectable Metastatic Colorectal Cancer
2
Liver Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Recurrence, Local
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
7
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
derazantinib
2
Leucovorin
2
trametinib
1
tislelizumab
1
silmitasertib
1
seribantumab
1
pertuzumab
1
olutasidenib
1
galactomannan
1
exatecan
1
durvalumab
1
becatecarin
1
Tegafur
1
Standard of Care
1
S 1 (combination)
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microscopy, Confocal
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bile Duct Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts